Citigroup Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $7

Benzinga · 01/06 18:38
Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $9 to $7.